Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10750)	3/2/2004 4:17:22 PM
From: quidditch	Respond to of 52153

<<yeah, they need to get market share in a hurry....>> Whether it's NBIX's own PR blitz or a wake-up call on valuation for the market value of sleep medications, NBIX is doing quite nicely today. Certainly a lot of focus now on this indication. Separately, S&P ups SEPR outlook: <<NEW YORK, March 1 (Reuters) - Standard & Poor's on Monday raised its long-term outlook on Sepracor Inc. (SEPR - news) to "positive" from "stable," saying the specialty pharmaceutical company's new insomnia treatment Estorra could significantly diversify the company's revenue stream. At the same time, S&P affirmed Sepracor's corporate credit rating of "B," its fifth-highest junk rating. Sepracor has about $1.2 billion of debt, S&P said in a statement. Sepracor on Saturday said it received conditional U.S. approval for the sleep drug, which can be used both to trigger sleep and to maintain it through the night, as opposed to other products that are just approved for the onset of sleep. >> quid